Novartis registers new Phase IIIb IgAN trial and VEXAS Phase 2; gMG trial still activeSep 30Weekly roundup, 7 itemsarumakimigatrasentanUpdated
FDA approves new efficacy supplement for Novartis's FabhaltaJul 16Regulatory decisioniptacopanNovartis
Sign inSign in